Why did PSYBF stock fall so sharply today?

PSYBF stock dropped **-99.98%** to **$0.000001** mainly due to extreme illiquidity and large order imbalances. No new public earnings or scheduled announcements explain the move; thin volume (8,000 shares) amplified price swings.

What is Meyka AI’s view of PSYBF stock?

Meyka AI rates PSYBF **62.58/100** (Grade B, HOLD). The score weighs benchmark and sector comparisons, financial growth, key metrics and forecasts. This is informational and not investment advice.

Are there realistic price targets for PSYBF stock?

Scenario targets: bear **$0.000001**, base **$0.000010**, stretch **$0.00500** (year high). Targets assume restored liquidity and positive company catalysts; treat them as high-risk scenarios.

What should traders watch next for PSYBF stock?

Watch confirmed volume pickup, exchange notices, SEC filings and company announcements. Verify live quotes before trading and use limit orders because spreads and quote reliability are poor.

US Stocks

PSYBF (PsyBio PNK) -99.98% to $0.000001 on 25 Feb 2026: next steps

ByHuzaifa Zahoor February 25, 2026

PSYBF stock plunged -99.98% to $0.000001 on 25 Feb 2026 during U.S. market hours, marking one of the largest one-day declines among small-cap biotech names. Volume reached 8,000 shares versus an average of 16,227, while market cap stood at roughly $1,275.00 (USD) on the PNK exchange. The move pushed PsyBio Therapeutics Corp. (PSYBF) — a Healthcare/Biotechnology issuer — to the top losers list and tightened liquidity for traders and holders. We use Meyka AI-powered market analysis to connect key ratios, trading signals and price forecasts to today’s drop.